公开(公告)号：US20090197907A1

公开(公告)日：2009-08-06

申请号：US10598846

申请日：2005-04-01

申请人： Bandi Parthasaradhi Reddy ,  Kura Rathnakar Reddy ,  Rapolu Raji Reddy ,  Dasari Muralidhara Reddy ,  Kesireddy Subash Chander Reddy

发明人： Bandi Parthasaradhi Reddy ,  Kura Rathnakar Reddy ,  Rapolu Raji Reddy ,  Dasari Muralidhara Reddy ,  Kesireddy Subash Chander Reddy

IPC分类号： C07D221/06 ,  A61K31/44

CPC分类号： C07D401/14

摘要： The present invention relates to a novel crystalline form of rupatadine free base, process for its preparation and to a pharmaceutical composition containing it. In accordance with the present invention rupatadine is suspended in n-hexane, n-heptane, cyclohexane, diethyl ether or diisopropyl ether, stirred for at least 1 hour, filtered the solid and dried to give crystalline rupatadine form-B. The isolation of novel rupatadine free base as crystalline form-B may be useful as a purification of rupatadine or a salt thereof.

摘要翻译： 本发明涉及一种新型的卢卡达定游离碱的结晶形式，其制备方法和含有它的药物组合物。 根据本发明，将布他他他悬浮在正己烷，正庚烷，环己烷，乙醚或二异丙醚中，搅拌至少1小时，过滤固体，干燥，得到结晶的布他他汀B型。 将新型的卢卡达定游离碱分离为结晶形式-B可用作卢卡达定或其盐的纯化。

公开(公告)号：US20090082572A1

公开(公告)日：2009-03-26

申请号：US11718273

申请日：2005-11-14

申请人： Bandi Parthasaradhi Reddy ,  Kura Rathnakar Reddy ,  Rapolu Raji Reddy ,  Dasari Muralidhara Reddy

发明人： Bandi Parthasaradhi Reddy ,  Kura Rathnakar Reddy ,  Rapolu Raji Reddy ,  Dasari Muralidhara Reddy

IPC分类号： C07D401/12

CPC分类号： C07D401/12

摘要： The present invention relates to a commercially viable process for preparation of amorphous esomeprazole. Thus, amorphous esomeprazole is prepared by suspending esomeprazole in water and then subjecting the suspension to lyophilization at −70° C.

摘要翻译： 本发明涉及用于制备无定形艾美拉唑的商业上可行的方法。 因此，通过将艾美拉唑悬浮在水中然后在-70℃下将悬浮液冻干来制备无定形艾美拉唑

公开(公告)号：US20090054682A1

公开(公告)日：2009-02-26

申请号：US11718359

申请日：2005-11-25

申请人： Bandi Parthasaradhi Reddy ,  Kura Rathnakar Reddy ,  Rapolu Raji Reddy ,  Dasari Muralidhara Reddy ,  Kesireddy Subash Chander Reddy

发明人： Bandi Parthasaradhi Reddy ,  Kura Rathnakar Reddy ,  Rapolu Raji Reddy ,  Dasari Muralidhara Reddy ,  Kesireddy Subash Chander Reddy

IPC分类号： C07C227/14

CPC分类号： C07C247/14 ,  C07C231/12 ,  C07C2601/16 ,  C07C233/52

摘要： The present invention provides an improved and commercially viable process for the preparation of oseltamivir phosphate. Thus, for example, ethyl (3R,4R,5S)-4-amino-5-azido-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate is acetylated with acetic anhydride in methylene chloride in the presence of triethyl amine in the absence of water to give ethyl (3R,4R,5S)-4-(acetylamino)-5-azido-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate.

摘要翻译： 本发明提供了一种改进和商业上可行的磷酸奥司他韦的制备方法。 因此，例如，在三水合物存在下，将（3R，4R，5S）-4-氨基-5-叠氮基-3-（1-乙基丙氧基）-1-环己烯-1-羧酸乙酯与乙酸酐在二氯甲烷中乙酰化 （3R，4R，5S）-4-（乙酰氨基）-5-叠氮基-3-（1-乙基丙氧基）-1-环己烯-1-羧酸乙酯。

公开(公告)号：US20080281093A1

公开(公告)日：2008-11-13

申请号：US10595544

申请日：2004-11-01

申请人： Bandi Parthasaradhi Reddy ,  Kura Rathnakar Reddy ,  Rapolu Raji Reddy ,  Dasari Muralidhara Reddy ,  Nagabelli Murali

发明人： Bandi Parthasaradhi Reddy ,  Kura Rathnakar Reddy ,  Rapolu Raji Reddy ,  Dasari Muralidhara Reddy ,  Nagabelli Murali

IPC分类号： C07D501/04 ,  C07F7/02

CPC分类号： C07D501/22 ,  C07F7/188

摘要： The present invention relates to a process for preparing a key intermediate of cefprozil and use of this intermediate in the preparation of cefprozil thereby avoiding impurity-causing self-acylation. [R-(Z)]-[4-hydroxy-α-[(3-methoxy-1-methyl-3-oxo-1-propenyl)amino]]benzeneacetic acid, mono potassium salt is reacted with ethyl chloroformate to obtain mixed anhydride which is then silylated with N,O-bis(trimethylsilyl)acetamide. The silylated compound obtained is reacted with [7-trimethylsilylamino-3-(Z/E-propen-1-yl)-3-cephem-4-carboxylic acid]trimethylsilyl ester and deprotected with aqueous hydrochloric acid to give cefprozil.

摘要翻译： 本发明涉及一种制备头孢司定的关键中间体的方法，并且在制备头孢丙烯时使用该中间体，从而避免杂质自身酰化。 [R-（Z）] - [4-羟基-α-[（3-甲氧基-1-甲基-3-氧代-1-丙烯基）氨基]]苯乙酸，单钾盐与氯甲酸乙酯反应，得到混合 酸酐，然后用N，O-双（三甲基甲硅烷基）乙酰胺进行甲硅烷基化。 所得甲硅烷基化的化合物与[7-三甲基甲硅烷基氨基-3-（Z / E-丙烯-1-基）-3-头孢烯-4-羧酸]三甲基甲硅烷基酯反应，并用盐酸水溶液脱保护，得到头孢丙烯。

公开(公告)号：US20080182856A1

公开(公告)日：2008-07-31

申请号：US11870108

申请日：2007-10-10

申请人： Bandi Parthasaradhi Reddy ,  Kura Rathnakar Reddy ,  Rapolu Raji Reddy ,  Dasari Muralidhara Reddy ,  Kesireddy Subash Chander Reddy

发明人： Bandi Parthasaradhi Reddy ,  Kura Rathnakar Reddy ,  Rapolu Raji Reddy ,  Dasari Muralidhara Reddy ,  Kesireddy Subash Chander Reddy

IPC分类号： A61K31/496 ,  C07D401/02

CPC分类号： C07D215/227 ,  C07B2200/13 ,  C07D215/22

摘要： The present invention provides novel crystalline forms of aripiprazole and aripiprazole hydrochloride, processes for their preparation and pharmaceutical compositions containing them.

公开(公告)号：US20080085903A1

公开(公告)日：2008-04-10

申请号：US11870067

申请日：2007-10-10

申请人： Bandi Parthasaradhi Reddy ,  Kura Rathnakar Reddy ,  Rapolu Raji Reddy ,  Dasari Muralidhara Reddy ,  Kesireddy Subash Chander Reddy

发明人： Bandi Parthasaradhi Reddy ,  Kura Rathnakar Reddy ,  Rapolu Raji Reddy ,  Dasari Muralidhara Reddy ,  Kesireddy Subash Chander Reddy

IPC分类号： A61K31/497 ,  C07D401/02

CPC分类号： C07D215/227 ,  C07B2200/13 ,  C07D215/22

摘要： The present invention provides novel crystalline forms of aripiprazole and aripiprazole hydrochloride, processes for their preparation and pharmaceutical compositions containing them.

摘要翻译： 本发明提供阿立哌唑和阿立哌唑盐酸盐的新型结晶形式，其制备方法和含有它们的药物组合物。

公开(公告)号：US20060089386A1

公开(公告)日：2006-04-27

申请号：US10503830

申请日：2004-04-28

申请人： Bandi Parthasaradhi Reddy ,  Kura Rathnakar Reddy ,  Rapolu Raji Reddy ,  Dasari Muralidhara Reddy

发明人： Bandi Parthasaradhi Reddy ,  Kura Rathnakar Reddy ,  Rapolu Raji Reddy ,  Dasari Muralidhara Reddy

IPC分类号： A61K31/4439 ,  C07D401/02

CPC分类号： C07D401/12

摘要： The present invention relates to a process for preparing substituted sulfoxides either as a single enantiomer or in an enantiomerically enriched form. Thus, racemic omeprazole is reacted with (S)-camphorsulfonyl chloride to form a diastereomeric mixture and the diastereomers are separated by fractional crystallization, followed by deprotection to give esomeprazole.

摘要翻译： 本发明涉及作为单一对映异构体或以对映体富集形式制备取代亚砜的方法。 因此，外消旋奥美拉唑与（S） - 樟脑磺酰氯反应以形成非对映异构体混合物，通过分级结晶分离非对映体，然后脱保护得到艾美拉唑。

公开(公告)号：US09150547B2

公开(公告)日：2015-10-06

申请号：US13989541

申请日：2011-11-11

申请人： Bandi Parthasaradhi Reddy ,  Kura Rathnakar Reddy ,  Dasari Muralidhara Reddy ,  Thungathurthy Srinivasa Rao ,  Bandi Vamsi Krishna

发明人： Bandi Parthasaradhi Reddy ,  Kura Rathnakar Reddy ,  Dasari Muralidhara Reddy ,  Thungathurthy Srinivasa Rao ,  Bandi Vamsi Krishna

IPC分类号： C07D403/12 ,  C07D239/42

CPC分类号： C07D403/12 ,  C07D239/42

摘要： The present invention provides a commercially viable process for preparing pazopanib and its pharmaceutically acceptable acid addition salts thereof in high yields using novel intermediate. The present invention also provides a process for the purification of pazopanib hydrochloride.

摘要翻译： 本发明提供了使用新型中间体以高产率制备比唑帕尼及其药学上可接受的酸加成盐的商业上可行的方法。 本发明还提供了盐酸帕唑帕尼的纯化方法。

公开(公告)号：US08703788B2

公开(公告)日：2014-04-22

申请号：US13989602

申请日：2011-11-11

申请人： Bandi Parthasaradhi Reddy ,  Kura Rathnakar Reddy ,  Dasari Muralidhara Reddy ,  Thungathurthy Srinivasa Rao ,  Bandi Vamsi Krishna

发明人： Bandi Parthasaradhi Reddy ,  Kura Rathnakar Reddy ,  Dasari Muralidhara Reddy ,  Thungathurthy Srinivasa Rao ,  Bandi Vamsi Krishna

IPC分类号： A01N43/54 ,  A61K31/505

CPC分类号： C07D401/14 ,  A61K31/506

摘要： The present invention provides a novel crystalline form of nilotinib hydrochloride, process for its preparation and pharmaceutical compositions comprising it.

摘要翻译： 本发明提供了盐酸尼洛替尼的新型结晶形式，其制备方法和包含其的药物组合物。

公开(公告)号：US09624236B2

公开(公告)日：2017-04-18

申请号：US13530844

申请日：2012-06-22

申请人： Bandi Parthasaradhi Reddy ,  Kura Rathnakar Reddy ,  Dasari Muralidhara Reddy ,  Rapolu Raji Reddy ,  Kesireddy Subash Chander Reddy ,  Bandi Vamsi Krishna

发明人： Bandi Parthasaradhi Reddy ,  Kura Rathnakar Reddy ,  Dasari Muralidhara Reddy ,  Rapolu Raji Reddy ,  Kesireddy Subash Chander Reddy ,  Bandi Vamsi Krishna

IPC分类号： A01N43/08 ,  A61K31/34 ,  C07D493/04 ,  A61K9/20

CPC分类号： C07D493/04 ,  A61K9/2027 ,  A61K9/2054 ,  A61K31/34

摘要： Described herein is pure amorphous darunavir, methods of making pure amorphous darunavir and pharmaceutical compositions containing amorphous darunavir and a pharmaceutically acceptable excipient.